Radient Technologies (TSXV:RTI) released an update on the development of its facility expansion, its Access to Cannabis for Medical Purposes Regulations (ACMPR) license and its business in Europe.

As quoted in the press release:


Expansion of Manufacturing Capacity

Further to its previously announced expansion plans, the capacity expansion of Radient’s existing manufacturing facility is now nearing completion, with construction expected to be completed by the end of June 2018.  The expansion provides a new processing line dedicated exclusively to intermediate and end-use products using extracted THC, and makes use of a number of new innovations in Radient’s proprietary extraction platform. Commissioning of the expanded facility is anticipated through the summer of 2018. As previously announced, Radient recently acquired two parcels of land adjacent to the facility, providing more than 80,000 sq. ft. of additional real estate for subsequent future capacity expansions and additions to Radient’s extraction and product development capabilities.

Cannabis Extraction Operations

Radient’s manufacturing facility (including the expansion) is located approximately 20 kilometers from the Aurora Sky facility owned by Aurora Cannabis Inc. (“Aurora”) (TSX: ACB) (OTCQB:ACBFF) (Frankfurt: 21P; WKN: A1C4WM), and approximately 575 Kilometres from the site in southern Alberta where the Aurora Sun facility is being built. Aurora holds an approximately 17% ownership interest in Radient, and in November 2017, the companies entered into a Master Services Agreement (“MSA”) for the extraction of cannabinoids. Aurora has recently announced its intention to acquire MedReleaf Corp., which upon completion will create a global cannabis company with 570,000 kg per annum in funded capacity in Canada and the EU. The MedReleaf acquisition, upon completion, is expected to be accretive to Radient, as the new combination will require significant additional extraction capacity as can be delivered by Radient through its high throughput technology.

Click here to read the full press release.

Source: globenewswire.com

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less